EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Targeting of Mutant Isocitrate Dehydrogenase in Glioma: A Systematic Review

Tyler A Lanman, L Nicolas Gonzalez Castro iD

Cancers · 12.08.2025 · 17 (16) · 2630

DOI: 10.3390/cancers17162630 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 12.08.2025. Verfasst von Tyler A Lanman und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Mutant isocitrate dehydrogenase (IDH) inhibitors represent a major advance in precision oncology. The recent Food and Drug Administration approval of vorasidenib for IDH-mutant glioma highlights its therapeutic potential in this setting. As this and other mutant IDH inhibitors enter the clinical setting, providers are tasked with staying informed of the evolving therapeutic landscape as more is learned about this unique class of medications. We aimed to summarize insights from preclinical studies and clinical trials exploring their use in IDH-mutant glioma.

Methods

We reviewed notable preclinical studies establishing the rationale for targeting mutant IDH. We performed a systematic review of clincaltrials.gov to identify both completed and ongoing interventional IDH-directed trials in patients with IDH-mutant glioma.

Results

We identified 8 published and 15 ongoing clinical trials evaluating IDH-directed therapies. IDH inhibitors have been shown to slow and, in some cases, reverse glioma tumor growth, with activity that may extend beyond their currently approved indications. The presence of contrast enhancement is consistently a negative predictor of response for ivosidenib and vorasidenib, although safusidenib and olutasidenib preliminarily may retain efficacy in these cases. Novel approaches such as IDH-directed vaccines and combination therapy using mutant IDH inhibitors with immunotherapy are currently under active investigation.

Conclusions

Mutant IDH inhibition is a promising, well-tolerated, and evolving approach for many patients with IDH-mutant glioma. Ongoing research will clarify its optimal clinical utility and potentially expand its indication.

Schlagwörter

Stichwörter der Autor:innen

IDH inhibitorIDH-mutant gliomaINDIGOgliomaisocitrate dehydrogenaseivosidenibprecision oncologyprimary brain tumorssystematic reviewvorasidenib

Autor:innen und Institutionen

  • Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
  • Department of Neurology, Harvard Medical School, Boston, MA 02115, USA.
  • Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, MA 02115, USA.
  • Department of Neurology, University of Washington, Seattle, WA 98195, USA.
  • Department of Neurology, Brigham and Women's Hospital, Mass General Brigham, 60 Fenwood Rd, Boston, MA 02115, USA.
  • Center for Tumors of the Nervous System, Mass General Brigham Cancer Institute, Boston, MA 02114, USA.

ORCID-Profile: L Nicolas Gonzalez Castro

Zitieren

APA

Lanman, T. A., & Gonzalez Castro, L. N. (2025). Targeting of Mutant Isocitrate Dehydrogenase in Glioma: A Systematic Review. Cancers, 17(16), 2630. https://doi.org/10.3390/cancers17162630

Vancouver

Lanman TA, Gonzalez Castro LN. Targeting of Mutant Isocitrate Dehydrogenase in Glioma: A Systematic Review. Cancers. 2025;17(16):2630. doi:10.3390/cancers17162630

BibTeX
@article{Lanman2025,
  author = {Lanman, Tyler A and Gonzalez Castro, L Nicolas},
  title = {Targeting of Mutant Isocitrate Dehydrogenase in Glioma: A Systematic Review},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {16},
  pages = {2630},
  doi = {10.3390/cancers17162630}
}
Kostenlos starten →